Literature DB >> 6095115

Production of functional chimaeric mouse/human antibody.

G L Boulianne, N Hozumi, M J Shulman.   

Abstract

The availability of monoclonal antibodies has revived interest in immunotherapy. The ability to influence an individual's immune state by administering immunoglobulin of the appropriate specificity may provide a powerful approach to disease control and prevention. Compared with immunoglobulin from other species, human immunoglobulin (Ig) might be best for such therapeutic intervention; it might function better with the recipient's effector cells and should itself be less immunogenic. The success of the mouse hybridoma system suggests that immunoglobulin of virtually any specificity can be obtained from a properly immunized animal. In the human system, however, immunization protocols are restricted by ethical considerations, and it is not yet clear whether human antibody-producing cell lines of the required specificity can be obtained from adventitiously immunized individuals or from in vitro immunized cells. A method which might circumvent these difficulties is to produce antibodies consisting of mouse variable regions joined to human constant regions. Therefore, we have constructed immunoglobulin genes in which the DNA segments encoding mouse variable regions specific for the hapten trinitrophenyl (TNP) are joined to segments encoding human mu and kappa constant regions. These 'chimaeric' genes are expressed as functional TNP-binding chimaeric IgM. We report here some of the properties of this novel IgM.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095115     DOI: 10.1038/312643a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  92 in total

Review 1.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 2.  Protein-based tumor molecular imaging probes.

Authors:  Xin Lin; Jin Xie; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-17       Impact factor: 3.520

Review 3.  [Therapeutic monoclonal antibodies in clinical neurology].

Authors:  M Buttmann; H Wiendl
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

Review 4.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

5.  Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor.

Authors:  Tomohiro Osaki; Cai-Xia Wang; Taro Tachibana; Masayuki Azuma; Masaya Kitamura; Takeshi Nakanishi
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-12

Review 6.  Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.

Authors:  Jamie Campbell; David Lowe; Matthew A Sleeman
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 7.  Cancer nanomedicines: so many papers and so few drugs!

Authors:  Vincent J Venditto; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

8.  A humanized antibody that binds to the interleukin 2 receptor.

Authors:  C Queen; W P Schneider; H E Selick; P W Payne; N F Landolfi; J F Duncan; N M Avdalovic; M Levitt; R P Junghans; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer.

Authors:  H Kobayashi; H Sakahara; T Saga; M Hosono; M Shirato; H Kanda; K Ishibashi; T Watanabe; K Endo; I Ishiwata
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

10.  Humanized antibodies for antiviral therapy.

Authors:  M S Co; M Deschamps; R J Whitley; C Queen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.